Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Paola Carluccio et al.|The Lancet Haematology|2017Cited by 163
Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeMaria Antonietta Aloe Spiriti, Maria Concetta Petti, Roberto Latagliata et al.|Annals of Hematology|2004Cited by 110
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacyEsther Natalie Olíva, Maria Antonietta Aloe Spiriti, Roberto Latagliata et al.|Leukemia & lymphoma/Leukemia and lymphoma|2013Cited by 30
Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletionEsther N. Oliva, Roberto Latagliata, Maria Cuzzola et al.|European Journal Of Haematology|2010Cited by 29
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II studyEsther Natalie Olíva, Roberto Latagliata, Maria Cuzzola et al.|Annals of Hematology|2012Cited by 27